Abstracts Archive - Page 361 of 1683 - ATC Abstracts

2020 American Transplant Congress
The Level of Plasm Donor-Derived Cell-Free DNA in Kidney Transplant Patients with Severe Pneumonia
L. Liu¹, H. Liu², F. Liu², L. Shu², L. Peng¹
¹Xiangyang Hospital No. 2 of Central South University, Changsha, China, ²AlloDx, Shanghai; Suzhou, China
*Purpose: Pulmonary infection is one of the common complications after kidney transplantation. Donor-derived cell-free DNA (ddcfDNA) is a new biomarker to diagnose allograft injury. Currently,…
2020 American Transplant Congress
Mycophenolate Mofetil and the Incidence of Skin Cancer in Kidney Transplant Recipients
S. J. Yusuf¹, H. Bheemreddy¹, A. Imtiaz², N. Krishnan³
¹Faculty of Health and Life Sciences, Coventry University, Coventry, United Kingdom, ²Dermatology, University Hospital Coventry and Warwickshire NHS Trust, Coventry, United Kingdom, ³Renal Unit, University Hospital Coventry and Warwickshire NHS Trust, Coventry, United Kingdom
*Purpose: Over the years there has been a shift in the use of anti-metabolites agents from azathioprine to mycophenolate mofetil (MMF) based immunosuppression., due to…
2020 American Transplant Congress
Cytomegalovirus Preemptive Monitoring Conversion and the Use of a Preemptive Threshold after Solid Organ Transplant
C. Wong, M. Jorgenson, J. Descourouez, C. Saddler, J. Smith, D. Mandelbrot
UWHC, Madison, WI
*Purpose: Cytomegalovirus (CMV) in solid organ transplant (SOT) is associated with negative graft and patient outcomes. Prophylactic agents of choice have substantial cytotoxicity, and patients…
2020 American Transplant Congress
Incidence and Outcomes of Secondary Cutaneous Malignancies among Renal Transplant Recipients
T. Maw¹, P. Vaidya¹, J. Samaan², S. Ghanshani¹, G. In¹
¹Keck School of Medicine, LA, CA, ²Cedar Sinai Hospital, LA, CA
*Purpose: Solid-organ transplant recipients on immunosuppressive therapy are known to have higher morbidity and mortality from secondary malignancies; however, there are no established guidelines for…
2020 American Transplant Congress
Incidence of Skin Cancer – A Long Term Outcome of Immunosuppression in Renal Transplant Recipients Associated with the Usage of Azathioprine
H. Bheemreddy¹, S. Yusuf¹, N. Krishnan², A. Imtiaz³
¹Health and Life Sciences, Coventry University, Coventry, United Kingdom, ²Renal Unit, University Hospital Coventry and Warwickshire NHS Trust, Coventry, United Kingdom, ³Department of Dermatology, University Hospital Coventry and Warwickshire NHS Trust, Coventry, United Kingdom
*Purpose: The main cause of mortality in Kidney Transplant Recipient’s (KTRs) is malignancy. The cancer incidence is increased by treating with immunosuppressive agents and longer…
2020 American Transplant Congress
Impact of Organ Donor Infections on Kidney Transplant Recipient Outcomes
M. Santarossa¹, C. Muran², S. Sanchez², L. Heinrich², J. Yoo³, F. Albarillo¹, S. Akkina³, N. Clark¹, G. Reid¹
¹Department of Medicine, Division of Infectious Diseases, Loyola University Medical Center, Maywood, IL, ²Department of Pharmacy, Loyola University Medical Center, Maywood, IL, ³Department of Medicine, Division of Transplant Nephrology, Loyola University Medical Center, Maywood, IL
*Purpose: Donor-derived infections can lead to significant morbidity and mortality in organ transplant recipients. There is variability by center on treatment of positive donor cultures…
2020 American Transplant Congress
Cancer Risk in Living Kidney Donors (LKDs) in the United States
E. Engels¹, K. Yu¹, S. Brown¹, K. Pawlish², C. Lynch³, B. Kasiske⁴, J. Snyder⁴, R. Pfeiffer¹
¹National Cancer Institute, Bethesda, MD, ²New Jersey Dept of Health, Trenton, NJ, ³Univ of Iowa, Iowa City, IA, ⁴Scientific Registry of Transplant Recipients, Minneapolis, MN
*Purpose: Individuals who wish to donate a kidney for transplantation are evaluated for transmissible diseases (including cancer) prior to donation. Outcomes in LKDs after donation…
2020 American Transplant Congress
Live Donor Liver Transplant Offers Higher Survival, Improved Quality of Liver and Lower Morbidity for Recipients with Low MELD Score
M. Black, J. Bayer, H. Fernandez, E. Martinez, G. McKenna, N. Onaca, R. Ruiz, G. Testa, A. Wall, T. Ma, G. Saracino, S. Asrani, A. Gupta
Baylor University Medical Center, Dallas, TX
*Purpose: The shortage of cadaveric liver grafts contributes to significant waitlist mortality. Patients with low MELD-Na score (
2020 American Transplant Congress
Viral Kinetics of De Novo HCV Infection and Response to Antiviral Therapy in Liver and Kidney Transplant Recipients Receiving HCV-Viremic Donors
N. Terrault¹, J. Burton², E. Verna³, C. Mobley⁴, D. Victor⁴, J. Trotter⁵, C. Niemann⁶, R. Rubin⁷
¹University of Southern California, Los Angeles, CA, ²UC, Denver, CO, ³Columbia Universeity, New York, NY, ⁴Houston Methodist, Houston, TX, ⁵Baylor University, Dallas, TX, ⁶UCSF, San Francisco, CA, ⁷Piedmont Atlanta Hosptial, Atlanta, GA
*Purpose: There is general agreement that expanded use of organs from HCV-viremic donors is desirable, including in recipients without HCV infection. However, the optimal treatment…
2020 American Transplant Congress
Real-World Experiences in the Transplantation of Hepatitis C Positive Kidneys
J. M. Steinbrink, J. Byrns, L. Crona, M. Ellis, S. Sanoff, E. K. Maziarz, C. R. Wolfe
Duke University, Durham, NC
*Purpose: With advancements of direct-acting antivirals, transplantation of HCV-NAT+ (HCV+) organs to HCV-negative (HCV-) recipients has been used to decrease wait times without apparent sacrifice…